Is STTK or ZYME more profitable?

Shattuck Labs has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Zymeworks -126.92% -37.97% -25.31%

Is STTK or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Shattuck Labs (STTK) Competitors

$4.75 -0.12 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.89 +0.15 (+3.05%)

As of 07:02 PM Eastern

Compare

STTK vs. ZYME, ANIP, IOVA, LKFT, and OCUL

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Zymeworks (ZYME), ANI Pharmaceuticals (ANIP), Iovance Biotherapeutics (IOVA), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

How does Shattuck Labs compare to Zymeworks?

Shattuck Labs (NASDAQ:STTK) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Shattuck Labs presently has a consensus target price of $13.00, suggesting a potential upside of 173.68%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 56.06%. Given Shattuck Labs' higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Zymeworks had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 4 mentions for Zymeworks and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Zymeworks' score of 0.59 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Very Positive
Zymeworks	Positive

Shattuck Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Shattuck Labs has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	364.23	-$48.81M	-$0.63	N/A
Zymeworks	$105.96M	16.78	-$81.13M	-$1.37	N/A

Shattuck Labs has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Zymeworks	-126.92%	-37.97%	-25.31%

Summary

Zymeworks beats Shattuck Labs on 9 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

ANI Pharmaceuticals currently has a consensus price target of $107.33, suggesting a potential upside of 42.67%. Shattuck Labs has a consensus price target of $13.00, suggesting a potential upside of 173.68%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

ANI Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$923.71M	1.85	$78.34M	$3.95	19.05
Shattuck Labs	$1M	364.23	-$48.81M	-$0.63	N/A

ANI Pharmaceuticals has a net margin of 9.98% compared to Shattuck Labs' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Shattuck Labs	N/A	-60.73%	-55.75%

ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 1 articles in the media. Shattuck Labs' average media sentiment score of 1.89 beat ANI Pharmaceuticals' score of 1.14 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Shattuck Labs	Very Positive

Summary

ANI Pharmaceuticals beats Shattuck Labs on 8 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Iovance Biotherapeutics?

Shattuck Labs (NASDAQ:STTK) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Shattuck Labs has higher earnings, but lower revenue than Iovance Biotherapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	364.23	-$48.81M	-$0.63	N/A
Iovance Biotherapeutics	$263.50M	6.42	-$390.98M	-$0.95	N/A

Shattuck Labs has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Shattuck Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Shattuck Labs currently has a consensus price target of $13.00, indicating a potential upside of 173.68%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 122.39%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 21 more articles in the media than Shattuck Labs. MarketBeat recorded 22 mentions for Iovance Biotherapeutics and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Iovance Biotherapeutics' score of 0.29 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Very Positive
Iovance Biotherapeutics	Neutral

Summary

Shattuck Labs beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Lakefront Biotherapeutics American Depositary Shares?

Shattuck Labs (NASDAQ:STTK) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Very Positive
Lakefront Biotherapeutics American Depositary Shares	Positive

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Shattuck Labs. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	364.23	-$48.81M	-$0.63	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.44	$363.05M	-$1.41	N/A

Shattuck Labs currently has a consensus price target of $13.00, suggesting a potential upside of 173.68%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, suggesting a potential upside of 32.68%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

Shattuck Labs beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Ocular Therapeutix?

Shattuck Labs (NASDAQ:STTK) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Ocular Therapeutix had 7 more articles in the media than Shattuck Labs. MarketBeat recorded 8 mentions for Ocular Therapeutix and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Ocular Therapeutix's score of -0.17 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Very Positive
Ocular Therapeutix	Neutral

Shattuck Labs presently has a consensus target price of $13.00, suggesting a potential upside of 173.68%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 184.76%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs has higher earnings, but lower revenue than Ocular Therapeutix. Shattuck Labs is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	364.23	-$48.81M	-$0.63	N/A
Ocular Therapeutix	$51.95M	35.19	-$265.94M	-$1.46	N/A

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Shattuck Labs has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Shattuck Labs' return on equity of -60.73% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Summary

Shattuck Labs and Ocular Therapeutix tied by winning 8 of the 16 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$364.23M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-7.54	17.93	22.30	24.19
Price / Sales	364.23	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.65	6.63	9.84	6.72
Net Income	-$48.81M	$24.20M	$3.57B	$337.19M
7 Day Performance	-21.62%	-3.24%	-1.16%	0.48%
1 Month Performance	-32.05%	0.53%	3.85%	5.07%
1 Year Performance	365.69%	47.24%	27.40%	34.25%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	3.8982 of 5 stars	$4.75 -2.5%	$13.00 +173.7%	+366.0%	$364.23M	$1M	N/A	100	Positive News
ZYME Zymeworks	2.5532 of 5 stars	$25.40 -0.8%	$38.00 +49.6%	N/A	$1.85B	$105.96M	N/A	460	Analyst Forecast
ANIP ANI Pharmaceuticals	3.7369 of 5 stars	$81.41 -1.6%	$107.33 +31.8%	+20.6%	$1.85B	$883.37M	20.61	600	Positive News Analyst Forecast
IOVA Iovance Biotherapeutics	2.909 of 5 stars	$4.10 -0.2%	$8.43 +105.6%	+132.7%	$1.83B	$263.50M	N/A	500
LKFT Lakefront Biotherapeutics American Depositary Shares	2.5724 of 5 stars	$27.67 +0.7%	$36.50 +31.9%	-6.6%	$1.82B	$1.26B	N/A	1,310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. ZYME, ANIP, IOVA, LKFT, and OCUL

How does Shattuck Labs compare to Zymeworks?

Summary

How does Shattuck Labs compare to ANI Pharmaceuticals?

Summary

How does Shattuck Labs compare to Iovance Biotherapeutics?

Summary

How does Shattuck Labs compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Shattuck Labs compare to Ocular Therapeutix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. ZYME, ANIP, IOVA, LKFT, and OCUL

How does Shattuck Labs compare to Zymeworks?

Do institutionals & insiders hold more shares of STTK or ZYME?

Do analysts prefer STTK or ZYME?

Does the media refer more to STTK or ZYME?

Which has more volatility and risk, STTK or ZYME?

Which has better valuation and earnings, STTK or ZYME?

Is STTK or ZYME more profitable?

Summary

How does Shattuck Labs compare to ANI Pharmaceuticals?

Do analysts rate ANIP or STTK?

Which has higher earnings & valuation, ANIP or STTK?

Is ANIP or STTK more profitable?

Which has more risk & volatility, ANIP or STTK?

Do insiders & institutionals hold more shares of ANIP or STTK?

Does the media refer more to ANIP or STTK?

Summary

How does Shattuck Labs compare to Iovance Biotherapeutics?

Which has higher valuation & earnings, STTK or IOVA?

Is STTK or IOVA more profitable?

Which has more risk and volatility, STTK or IOVA?

Do analysts prefer STTK or IOVA?

Do institutionals and insiders believe in STTK or IOVA?

Does the media favor STTK or IOVA?

Summary

How does Shattuck Labs compare to Lakefront Biotherapeutics American Depositary Shares?

Is STTK or LKFT more profitable?

Do institutionals & insiders hold more shares of STTK or LKFT?

Does the media favor STTK or LKFT?

Which has more risk and volatility, STTK or LKFT?

Which has higher earnings & valuation, STTK or LKFT?

Do analysts recommend STTK or LKFT?

Summary

How does Shattuck Labs compare to Ocular Therapeutix?

Does the media favor STTK or OCUL?

Do analysts recommend STTK or OCUL?

Do institutionals and insiders hold more shares of STTK or OCUL?

Which has preferable valuation & earnings, STTK or OCUL?

Which has more volatility and risk, STTK or OCUL?

Is STTK or OCUL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools